Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$451.77M$451.77Mderived+51.6% vs Q4 2024 Net Income-$141.59M-$141.59MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$92,891,000N/M Operating Cash Flowderived$219,029,000+22.7% Free Cash Flowderived$217,602,000+24.0% Margins · derivedOperating margin-20.6%−79.5 pt vs Q4 2024
Net margin-31.3%−77.3 pt vs Q4 2024
ended Dec 31, 2025 · filed Feb 17, 2026 · 48 d after period end